Case Studies

New Capabilities

Treatment decision-making in healthcare is increasingly complex, and is shifting the role, makeup, and priorities of customers within a practice. With enhanced focus on efficiency and value-based medicine, many practices have evolved to extend decision-making beyond the physician into patient care teams comprised of the MD, patient, advanced practice providers, and other HCPs. These customers require …

New Horizons

Blue Matter worked with a mid-sized oncology organization to help develop a robust disease area and portfolio strategy to support the evolution of its oncology franchise towards global leadership. Companies need to take appropriate risks to grow and become market leaders. The risk associated with a failed growth strategy is especially costly in the biopharmaceutical …

Flawless Launch

Blue Matter helped a leading global biotech organization with the launch strategy and planning for a novel oncology therapy with breakthrough designation that launched in an accelerated timeline, significantly ahead of schedule. Launch of a novel bio-pharmaceutical product is one of the most important milestones in the product lifecycle. It typically takes a new molecular …

Building Blocks

Blue Matter worked with a mid-sized oncology diagnostic company to assist in the planning and development of Ex-US infrastructure and organizational capabilities to drive international growth. As companies expand their product portfolios and enter new markets (new segments or geographies), they face a significant challenge in growing their commercial infrastructure and capabilities required to support …

Peak Performance

Blue Matter worked with a leading biotech company to improve the performance of a marketed cardiovascular drug through local market segmentation and customized tactical execution to drive growth in discrete local markets. Once a product brand is launched and commercially available, brand teams’ primary goal is to reach peak performance, and to get there fast. …

Designed to Win

Blue Matter worked with a global biotechnology company to design the target product profile for a new asthma product in order to improve the probability of commercial success. Drug development is staggeringly costly and approximately 95% of experimental medicines that are studied in humans fail to clear the regulatory hurdle for final approval. In addition …